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Monocyte apoptosis in patients with active lupus 
The prcscncc of nucleosome polymers in the peri- 
pheral blood of patients with active systemic lupus erythema- 
tows (SLE) (1) suggests ongoing apoptosis. While the lympho- 
cyte population has been implicated as a source of these 
fragments (2), thc cells that release the chromatin are incom- 
pletely characterized. Our group has reported that patients 
with active lupus have a T cell subsct which spontaneously lyses 
autologous macrophagcs in vitro (3), and that murine T cells 
capable of inducing apoptosis in syngcneic macrophages will 
cause a lupus-like disease in vivo (4). These results suggest that 
monocyteimacrophage apoptosis may occur in patients with 
active lupus. Wc therefore sought to determine whcthcr pa- 
tients with active lupus have evidence of ongoing monocyte 
apop tosis. 
Patients with active lupus were recruited from the 
inpatient rheumatology servicc and outpatient clinics at the 
A 
University of Michigan, and paticnts with inactive lupus and 
active rheumatoid arthritis (RA) wcrc recruited from the 
outpatient clinics. Hcalthy control subjccts were obtained by 
advertising. Paticnts met the American College of liheumatol- 
ogy (formerly, the Amcrican Rhcumatism Association) criteria 
for the classification of SLE ( 5 )  or RA (6). SLE and KA 
activity were defined as previously described (3). Patients 
receiving cyclophosphamide were excluded from study. Some 
samples were stored as heparinized whole blood overnight at 
23°C. In these cases, care was taken to store both patient and 
control samples under identical conditions. All samples wcrc 
analyzed within 20 hours of phlebotomy. 
To detect apoptotic cells, peripheral blood mono- 
nuclear cells (PBMC) were isolated as described (3) ,  and 
stained with propidium iodidc (PI) and Hoescht 33342, and 
then analyzed by flow cytomctry (7,8). The lymphocyte, mono- 
cytc, and granulocyte populations were identified by forward 
and 90" light scatter and confirmed by staining with anti-CD3- 
FITC, anti-B1 -FITC, and anti-MO1-FITC (Coulter, Ilialeah, 
FL). Dead cells were identified by high PI staining, viable cells 
by low PI staining and 2N IIoescht DNA staining, and apo- 
ptotic cells by low PI staining and less than 2N Hoescht DNA 
staining (7,8). Where indicated, T cells were depletcd by 
rosetting with sheep erythrocytes (3), and the nonrosetting 
population was fixed and analyzed by transmission clcctron 
microscopy (TEM) as described (4). Differences between 
groups were tested by analysis of variance, using SYSTAT 
software (Evanston, IL), or by t-tests. 
PBMC were obtained from 10 paticnts with activc 
SLE, 8 patients with inactive SLE, 7 patients with activc RA, 
and 12 healthy controls. The cells were stained as describcd 
above, and the percentages of apoptotic monocytes and lym- 
phocytes were determined by flow cytometry. Figure 1A shows 
a representative histogram of monocytcs from a hcalthy con- 
trol. Figurc 1B shows monocytcs from a patient with active 
lupus analyzed similarly. In Figure lB, the population of cclls 
excluding PI, and containing less DNA than controls by 
Hoescht staining, contains thc apoptotic cells (7,8). 
Figure 2A shows that an average of 5% of the mono- 
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Figure 1. Peripheral blood mononuclear cells from A, a hcalthy control and R, a patient with activc lupus were 
stained with anti-MO1-FII'C, propidium iodidc, and Hocscht 33342 and analyzed using 3-color flow cytomctry. 
'I'hc monocytc population is shown. The x axis (Log DNA) rcprcscnts the intcnsity of thc Hocscht staining; thc 
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Figure 2. A, Monocytc (Mb) apoptosis was measured by flow cytometry in peripheral blood mononuclear cells 
isolated from the indicated groups. Each point represents an individual subject; squares with I-bars represent the 
mean i SEM of the subjects within each group. Patients with active systemic lupus erythematosus (SLE) had a 
greater percentage of monocytes undergoing apoptosis than did controls (1' = 0.007). B, I.ymphocyte apoptosis 
in the same subjects. The increase in lymphocyte apoptosis in the lupus patients was not significant at the P < 
0.05 level. C, Non-T cells from a patient with activc lupus, stained with toluidine blue. Arrowheads identify 
apoptotic monocytes (magnification X 1,000). D, Non-'T cells from a lupus patient, stained with uranyl acetate 
and imaged by transmission electron microscopy. Three erythrocytes and 2 monocytes are shown; one of the 
monocytcs is apoptotic (magnification X 3,200). RA = rheumatoid arthritis. 
cytes from patients with active lupus were undergoing apopto- 
sis, while <1% of monocytes from the other subjects wcrc 
apoptotic (P = 0.007). Figure 2B shows that a lesser number of 
lymphocytes from the same subjects were apoptotic, with an 
average of 2% for thc patients with active S I E  and 50.6% for 
the other groups. However, this difference was not statistically 
significant (P  = 0.06), possibly due to the number of subjects 
analyzed. 
Since some of the lupus patients had received cortico- 
steroids, the effcct of methylprednisolonc on monocyte apo- 
ptosis was examincd. Mood samples wcrc obtained before and 
after administration of 1 gm of methylprednisolone. No signif- 
icant increases were observed immediately (mean r+_ SEM 
0.85 t 0.35% before and 1.75 _f 1.34% after, n = 2) or up to 
3 days later (1.2% versus 0.5%). Furthcrmore, 5 of the SLE 
patients receiving a mean t SEM of 54 t 7.6 mgiday of 
prednisone had only 0.34 r+_ 0.16% apoptotic monocytes. 
Overall, the levcl of monocytc apoptosis was 4.2 t 1.9% in 
patients receiving 515 mg of prednisone/day, and 1.9 f 1.0% 
in patients receiving >I5  mgiday (P > 0.20). This finding 
supports thc notion that corticosteroids do not stimulate 
monocyte apoptosis. 
The prescnce of apoptotic monocytes was confirmed 
by morphology in 2 subjects with active SLE. Figure 2C shows 
a representative micrograph of freshly obtained and isolated 
non-T cells stained with toluidine bluc from one of thcsc 
subjects, and 2D shows a 1 E M  image. Monocytic cells show 
nuclear condensation, which is characteristic of apoptotic cells. 
Such cells were not seen in similar preparations from a normal 
subject (data not shown). To further examine the relationship 
between disease activity and monocyte apoptosis, two subjects 
with active SLE and increased numbers of circulating apopto- 
tic monocytes were retested following therapy and with remis- 
sion of symptoms. In both subjccts, the percentage of apoptotic 
monocytes dccreascd (from 8.1% to 096, and from 10% to 
3.1%). 
A recent report described accelerated lymphocyte apo- 
ptosis i n  patients with active SLE (2). Howcvcr, other cell types 
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were excluded from analysis in this study. Our results suggest 
that monocytes are also dying by apoptosis in patients with 
active lupus. Since some of the samples were analyzed 16-20 
hours after phlebotomy, it is possible that some degree of 
apoptosis began between the time of phlebotomy and the time 
of staining. However, in SLE patient samples analyzed within 
hours of phlebotomy, apoptotic monocytes were also seen. 
Furthermore, the ultrastructural studies were also performed 
on freshly isolated cells, and also showed apoptotic cells. This 
argues that at least some degree of monocyte apoptosis occurs 
in vivo. 
Earlier work suggested that cells other than just lym- 
phocytes undergo apoptosis in SLE patients. The hematoxylin 
body, characteristic of lupus (9,10), histologically and chemi- 
cally resembles apoptotic nuclei (ll), and is believed to derive 
from leukocytes, lymphocytes, macrophages, and endothelial 
cells (10). Apoptotic monocytes and lymphocytes may contrib- 
ute to the development of this structure. The signal-triggering 
apoptosis in these cells is unknown. The Fas molecule trans- 
mits an apoptosis-inducing signal in lymphocytes and mono- 
cytes (12,13), and is functional in SLE patients (13), which 
suggests a possible mechanism. Since a T cell subset capable of 
lysing syngeneic macrophages has been described in patients 
with active lupus (3), and T cells can express a Fas ligand (14), 
an autoreactive T cell subset could be responsible. Alterna- 
tively, monocyte and lymphocyte apoptosis could be the result 
of as yet unidentified stimuli generated during active disease. 
In either case, apoptotic cells could contribute to the patho- 
genesis of the disease. Recent evidence suggests that anti- 
DNA antibodies preferentially react with nucleosomes (15). 
Nucleosomal DNA fragments, released from apoptotic blood 
elements, could provide an antigen source contributing to the 
development of anti-DNA autoantibodies. 
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